Moreover, clinical evaluation of 1,794 breast cancer patients revealed that somatic p53 mutations are also associated with a shorter overall survival, independently of stage, grade, and hormone receptors status (10), similarly to other cancer types harboring mutp53 (1). This evidence concerns the gene TP53 and cancer.